Peptide library › Cancer & imaging
Lutetium Lu-177 vipivotide tetraxetan
Also known as Pluvicto, 177Lu-PSMA-617
Targeted radiation therapy for advanced prostate cancer that carries the PSMA protein.
What people use it for
- PSMA-positive metastatic castration-resistant prostate cancer
What Lutetium Lu-177 vipivotide tetraxetan does in the body
A small molecule that binds PSMA, a protein on most prostate cancer cells, carrying radioactive lutetium-177 to kill them.
Strength of evidence
Strong: the VISION trial improved survival; PSMAfore supported earlier use.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
- Prescribing information (DailyMed, US): Official US label
- Patient leaflets (emc, UK): Official UK product information
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Dry mouth
- Tiredness and nausea
- Low blood counts
- Kidney effects
Who should avoid it or take extra care
- Severe kidney impairment needs caution
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
FDA-approved in 2022, with its use widened in 2025 to some patients before chemotherapy. Specialist centres only.
How it's taken
Route: Infusion into a vein, every 6 weeks for up to 6 doses
How long it lasts (half-life): Lutetium-177 loses half its radioactivity every 6.7 days
Storage
Stored and prepared by the pharmacy or clinic, following the product label.
Latest research & news
- Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy
Clinical trial · Recruiting · Early phase 1 · Updated · ClinicalTrials.gov · 20 Nov 2026 - Pluvicto Real-world Investigation in Survival in Metastatic CRPC
Clinical trial · Recruiting · Updated · ClinicalTrials.gov · 20 Nov 2026 - STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
Clinical trial · Recruiting · Phase 1/2 · Updated · ClinicalTrials.gov · 18 Nov 2026 - Single-Time-Point Time-integrated Activity Estimation for Dosimetry in 177Lu-PSMA Therapy: Evaluation of Analytical and Machine Learning Methods
Research · Study · PubMed · Clin Nucl Med · 18 Nov 2026
Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.
Keep track of Lutetium Lu-177 vipivotide tetraxetan privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Lutetium Lu-177 vipivotide tetraxetan in Fiala How to installMore in Cancer & imaging
- DegarelixMonthly hormone-blocking injection for advanced prostate cancer that lowers testosterone fast, without an initial flare.
- Lutetium Lu-177 dotatateTargeted radiation therapy that delivers radiation straight to neuroendocrine tumours.
- Gallium Ga-68 dotatateRadioactive tracer used in PET scans to find neuroendocrine tumours.
- MotixafortideInjection that releases stem cells from the bone marrow so they can be collected before a transplant for multiple myeloma.
- BalixafortideExperimental CXCR4 blocker studied with chemotherapy for advanced breast cancer; its Phase 3 trial failed.
- LTX-315Experimental cancer-killing peptide injected directly into tumours to trigger an immune response.